Medicus Pharma (MDCX) Non Operating Income (2024 - 2025)
Medicus Pharma (MDCX) posted Non Operating Income of -$393957.0 for Q4 2025, up 29.01% quarter-over-quarter from -$554972.0 in Q3 2025, and down 905.69% year-on-year from $48897.0 in Q4 2024.
Medicus Pharma (MDCX) Non Operating Income (2024 - 2025) Analysis & Trends
Medicus Pharma (MDCX) has reported Non Operating Income for 2 consecutive years, with -$393957.0 the latest figure, recorded in Q4 2025.
- Non Operating Income for Q4 2025 came in at -$393957.0, down 905.69% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.1 million (down 4374.24% YoY), and the FY2025 annual result was -$1.1 million, down 4374.24% from the prior year.
- Non Operating Income was -$393957.0 for Q4 2025 at Medicus Pharma, up from -$554972.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $55514.0 in Q3 2024 and troughed at -$554972.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -65.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -294.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -2.31 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | -393,957.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -393,957.00 |
| Sep 30, 2025 | -554,972.00 |
| Jun 30, 2025 | -159,996.00 |
| Mar 31, 2025 | 23,866.00 |
| Dec 31, 2024 | 48,897.00 |
| Sep 30, 2024 | 55,514.00 |
| Jun 30, 2024 | -79,025.00 |